Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat in Advanced Renal Cell Carcinoma
NCT00278395Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2005
- Primary completion
- Feb 2010
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vorinostat in renal cell carcinoma (RCC), sponsored by National Cancer Institute. Primary endpoint: Objective Response at 1 year. Started Oct 2005; status: completed.
02
Drugs
vorinostat
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00278395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00278395.